Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AGEN

Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development

Agenus secures a $22M mortgage and announces a strategic realignment to focus on botensilimab/balstilimab in MSS colorectal cancer.

Benzinga

Search under way for French rugby player 'swept away by wave' in Cape Town

Mehdi Narjissi went missing while swimming near Cape of Good Hope

Evening Standard

Rugby transfer rumours and news: Exeter Chiefs linked with scrum-half, Gloucester add five Exiles

All the latest rugby transfer rumours and gossip, confirmed moves, retirements, contract renewals and the last breaking news from around the Gallagher Premiership

Bristol Post

From analysis to the latest developments in health,
read the most diverse news in one place.

Today's rugby news as French club aim to sign three Wales internationals in new twist

These are your rugby stories making headlines in Wales and around the world on Tuesday, June 20

Wales Online

From super fan to Leinster star - Garry Ringrose wants another 'pinch me moment' at the Aviva today

"When you’re coming up through academies, you’re always chasing something but to get to stand back and say, 'now I’m actually here'? It’s unbelievably special"

Irish Mirror

Impressive but easy canapes for festive entertaining

Forget smoked salmon and cream cheese. Upgrade your Christmas canape game with these minimal effort showstoppers from some of IndyEats’ favourite chefs

The Independent UK

Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal Cancer

Agenus Inc (NASDAQ:AGEN) has announced expanded data from the Phase 1b study of botensilimab and balstilimab in patients with microsatellite stable colorectal cancer. The data demonstrate that the combination offers strong durability and superior efficacy to what has been reported in separate trials for the standard of care and other investigational therapies. The…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Agenus's Return On Capital Employed Insights

According to Benzinga Pro data, during Q1, Agenus (NASDAQ:AGEN) posted sales of $25.94 million. Earnings were up 25.15%, but Agenus still reported an overall loss of $50.60 million.

Benzinga

Recap: Agenus Q1 Earnings

Agenus (NASDAQ:AGEN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Benzinga

Looking Into Agenus's Return On Capital Employed

Benzinga Pro data, Agenus (NASDAQ:AGEN) reported Q4 sales of $20.26 million. Earnings fell to a loss of $67.61 million, resulting in a 138.14% decrease from last quarter. Agenus earned $177.28 million, and sales totaled $252.95 million in Q3.

Benzinga

Recap: Agenus Q4 Earnings

Agenus (NASDAQ:AGEN) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Gallagher Premiership

28 stories

Trailfinders

27 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.